. 2017 Nov 7;84(1):97–111. doi: 10.1111/bcp.13400

Table 1a.

Overview of the population pharmacokinetic models used for the evaluation of drug–drug interactions for carbamazepine, clobazam, clonazepam, lamotrigine, levetiracetam and oxcarbazepine

Model	Carbamazepine	Clobazam*	Clonazepam	Lamotrigine Adults	Lamotrigine Children	Levetiracetam	Oxcarbazepine
First author	Jiao 13	Saruwatari 14	Yukawa 15	Rivas 16	He 17	Toublanc 18	Park 19
Population	Chinese	Japanese	Japanese	German, Spanish	Chinese	Japanese (model building), USA (validation)	Korean
Sample size (No.of patients)	585	85	137	284	600	259	199
Sample size (No.of patients)	687	128	259	404	1699	1833	254
Age (years)	1.2–85.1	1–52	0.3–32.6	26.8–51.3	0.5–17	4–55	3–80
Weight (kg)	5–115	8–102	5–90	61.8–85	6–98	14–107	10–95
Samples at	Trough	0–10 h after dose	2–6 h after dose	TDM	TDM	Random	TDM
Graphical representation
Parameters	K_a, V_c, CL	K_a, V_c,CL	K_a, V_c, CL	K_a, V_c, CL	K_a, V_c, CL	K_a, V_c, CL	K_a, V_c, CL
Between‐subject variability	V_c, CL	K_a, V_c,CL	V_c, CL	CL	CL	K_a, V_c, CL	CL
Covariate effects on CL	WT, Dose, PHB, PHT, VPA, Elderly (>65)	WT, PHB, PHT, ZNS, CYP2C19 & POR*28 genotypes	WT, CBZ, VPA	WT, CBZ, PHB, VPA	WT, CBZ, PHB, VPA	WT, CBZ, PHB, PHT, VPA	WT, CBZ, PHB, PHT
Covariate effects on V	WT	WT	WT	WT	WT	WT	WT

Simulations were performed only for the parent drug; the metabolite model not used CL, clearance; K_a, absorption rate constant; NA, not available; TDM, therapeutic drug monitoring; V, volume of distribution; V_c, volume of distribution of the central compartment; WT, weight